World Asthma Day 2026 - Where Are We With Respiratory Disease?

Updated: May 7, 2026 | Read time 5 mins

Beth Wright

‍

Why World Asthma Day 2026 matters more than ever

Asthma is a chronic respiratory disease affecting an estimated 363 million people worldwide and causing over 455,000 deaths annually (1). Despite being one of the most common non-communicable diseases globally, it remains undertreated, underdiagnosed, and misunderstood by the broader public.

World Asthma Day 2026 is an opportunity to change that. This year's Global Initiative for Asthma (GINA) theme, "Access to anti-inflammatory inhalers for everyone with asthma", is both a call to action and a reflection of how far we still have to go, but it also arrives at a moment of genuine momentum. Research is advancing, treatments are improving, and our understanding of asthma as a biological condition is being fundamentally reshaped.

‍

Asthma is not one disease

For decades, asthma has been treated as a single condition, and it was managed with the same inhaler, protocol and assumptions. We now know asthma is far more complex. Asthma is a heterogeneous disease, driven by distinct biological mechanisms and inflammatory pathways that vary significantly between patients (2-3). This is why two people with the same diagnosis can respond so differently to the same treatment. Understanding these subtypes (or endotypes) is central to improving care.

This growing understanding has led to the concept of “treatable traits”, a precision medicine approach that focuses on identifying and targeting the specific biological, physiological, and behavioural factors driving disease in each patient (4). Rather than asking "does this person have asthma?", clinicians increasingly ask "which traits are driving this person's asthma, and which of those can we treat?" It is a subtle but consequential shift in how we approach the disease.

‍

The shift away from the blue inhaler

One of the most significant changes in asthma management has been a rethinking of the "blue puffer", the short-acting bronchodilator that has long been the default response to symptoms.

GINA has now reinforced that inhaled corticosteroid (ICS)-containing therapies should be foundational in asthma management, even in mild disease (5). This reflects a broader shift toward treating the underlying airway inflammation that drives disease progression, not just relieving symptoms when they occur.

The Australian Asthma Handbook v3.0, published in September 2025, reflects this and recommendations include the anti-inflammatory reliever (AIR) and maintenance-and-reliever therapy (MART) approaches for adults and adolescents, and actively discouraging SABA-only care (6).

The clinical evidence supports this urgency. The BATURA trial demonstrated that as-needed albuterol-budesonide reduced severe exacerbation risk by 47% compared to albuterol alone, which reinforces that even mild asthma carries meaningful inflammatory risk, and that identifying and treating that trait early matters (7).

‍

New treatments are expanding what's possible

For patients with severe asthma, the past 12 months have brought two particularly important developments, both of which exemplify the treatable traits approach in practice.

Tezepelumab, a biologic targeting the upstream inflammatory mediator TSLP, published results from its WAYFINDER phase 3b study earlier this year. In patients with severe, uncontrolled asthma dependent on long-term oral corticosteroids, a population carrying significant steroid-related side effect burden, including osteoporosis, cataracts, and increased infection risk, nearly 90% reduced their daily steroid dose to 5mg or less, and over half discontinued oral corticosteroids entirely (8). Critically, benefits were seen across diverse patient subgroups regardless of inflammatory markers, suggesting Tezepelumab may target a trait present across multiple asthma endotypes.

Depemokimab (Exdensur), FDA approved in December 2025, represents a different kind of advance. As the first twice-yearly biologic for severe eosinophilic asthma, a well-defined treatable trait characterised by elevated eosinophil levels. It reduced annual exacerbation rates by 58% and 48% across the SWIFT trials, with the added benefit of its extended dosing interval reducing healthcare burden at a systems level (9).

These biologics are not just clinical breakthroughs. They are proof of concept that identifying and targeting the right biological trait in the right patient produces meaningfully better outcomes than a uniform approach.

‍

Environment, genetics, and the limits of medicine

While therapeutic advances are important, asthma outcomes are strongly influenced by environmental and lifestyle factors including air pollution, occupational exposures, tobacco and wildfire smoke, and high BMI (10). Importantly, many of these are themselves treatable traits: modifiable drivers of disease that, when identified and addressed, can reduce exacerbation risk and improve long-term outcomes independent of pharmacological intervention.

Genetics plays a similarly meaningful role. Asthma heritability is estimated to be as high as 74% in adults and up to 90% in children, with polygenic risk scores (PRS) increasingly being explored to identify at-risk individuals earlier in life (11). As these tools mature, they may support earlier identification of at-risk individuals before symptoms emerge, enabling trait-targeted prevention rather than reactive treatment.

Improving asthma outcomes will require more than better drugs alone. Prevention, environmental health, and equitable access to care remain essential.

‍

The frontier: precision diagnosis and nasal biomarkers

Perhaps the most exciting longer-term shift is the move toward precision diagnosis and identifying not just that someone has asthma, but which biological subtype they have, how severe their underlying inflammation is, and which treatable traits are present and actionable.

Nasal sampling is emerging as a promising approach, offering a window into airway inflammation without invasive procedures, enabling earlier diagnosis, real-time monitoring, and more personalised treatment decisions. This is still an emerging field, but the direction is clear: the future of asthma care lies in identifying the right traits in the right patient and delivering the right treatment at the right time.

‍

Where respiratory innovation goes from here

World Asthma Day 2026 is a moment to recognise genuine progress in treatment philosophy, in therapeutics, in our biological understanding of the disease. The treatable traits framework is bringing coherence to a field that has long struggled with heterogeneity, and new tools are making it increasingly possible to act on that understanding in clinical practice.

But progress in the clinic has not yet translated into equitable access, adequate prevention, or consistent diagnosis worldwide. The future of asthma care is not just better drugs. It is better diagnosis, better access, and better prevention for everyone.

What’s next for Diag-Nose in the asthma world

At Diag-Nose, we continue pursuing our goal of transforming respiratory diagnostics.

The ABEL microsampler is increasingly important in this space, enabling non-invasive, repeatable sampling and supporting improved biomarker detection.

As asthma care becomes more personalised, standardised nasal fluid collection devices, like the ABEL Microsampler, will play a key role in bridging the gap between research and clinical application.

‍

References

1. Wenzel SE. Asthma phenotypes: the evolution from clinical to molecular approaches. Nat Med. 2012;18(5):716–25.
2. Grunwell JR, Fitzpatrick AM. Asthma Phenotypes and Biomarkers. Respir Care. 2025.
3. Melhorn J, Howell I, Pavord ID. Should we apply a treatable traits approach to asthma care? Ann Allergy Asthma Immunol. 2022.
4. Global Initiative for Asthma (GINA). Global Strategy for Asthma Management and Prevention. 2025.
5. National Asthma Council Australia. Australian Asthma Handbook v3.0. 2025.
6. LaForce C, et al. As-needed albuterol–budesonide in mild asthma. N Engl J Med. 2025. As-Needed Albuterol–Budesonide in Mild Asthma | New England Journal of Medicine
7. Jackson D, Lugogo N, Gurnell M, et al. Oral corticosteroid reduction and discontinuation in adults with corticosteroid-dependent, severe, uncontrolled asthma treated with tezepelumab (WAYFINDER): a multicentre, single-arm, phase 3b trial. Lancet Respir Med. 2025;14:129–40. https://www.thelancet.com/journals/lanres/article/PIIS2213-2600(25)00359-5/fulltext
8. Jackson DJ, Wechsler ME, Bernstein D, Korn S, Pfeffer PE, et al. Twice-yearly depemokimab in severe asthma with an eosinophilic phenotype. N Engl J Med. 2024;391:2337–49. Twice-Yearly Depemokimab in Severe Asthma with an Eosinophilic Phenotype | New England Journal of Medicine
9. Soriano J, Kendrick P, Paulson K, et al. Prevalence and attributable health burden of chronic respiratory diseases, 1990–2017: a systematic analysis for the Global Burden of Disease Study 2017. Lancet Respir Med. 2020;8:585–96.
10. Savelieva O, Karunas A, Prokopenko I, Balkhiyarova Z, Gilyazova I, Khidiyatova I, Khusnutdinova E. Evaluation of Polygenic Risk Score for Prediction of Childhood Onset and Severity of Asthma. Int J Mol Sci. 2024;Dec 26;26(1):103.

‍